Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

Combined Screening with PlGF- Roche (Astraia) Test

The maximum days the report can be obtained for the Combined Screening with PlGF- Roche (Astraia) Test is 7 days.

What are the prerequisites for the test Combined Screening with PlGF- Roche (Astraia) Test

Prerequisites for Combined Screening with PlGF- Roche (Astraia) Test

  • Patient must be at least 18 years of age
  • Patient must be pregnant
  • Physician's referral for the test
  • No specific fasting or preparation required
  • No contraindications for blood testing
  • No known allergies to any components of the test
  • No recent blood transfusions

What are the measure values for the test Combined Screening with PlGF- Roche (Astraia) Test

Measure Value
Placental Growth Factor (PlGF) Low: <25 pg/mL
Roche (Astraia) Test Positive: >95 pg/mL

What does this test Combined Screening with PlGF- Roche (Astraia) Test identify?

  • Test Name: Combined Screening with PlGF- Roche (Astraia) Test
  • Identifies: This test is used to assess the risk of developing pre-eclampsia in pregnant women. Pre-eclampsia is a serious condition characterized by high blood pressure and damage to organs such as the liver and kidneys. It can be life-threatening for both the mother and the baby if not properly managed.
  • Method: The test combines the measurement of Placental Growth Factor (PlGF) levels in the maternal blood with other clinical and biochemical markers to calculate the individual risk of developing pre-eclampsia.
  • Importance: Early detection of pre-eclampsia risk allows for appropriate monitoring and interventions to prevent or manage the condition, leading to better outcomes for both the mother and the baby.

Why is this test Combined Screening with PlGF- Roche (Astraia) Test taken?

Reasons for Taking the Combined Screening with PlGF- Roche (Astraia) Test

The Combined Screening with PlGF- Roche (Astraia) Test is typically taken during pregnancy to assess the risk of certain complications that may affect both the mother and the baby. This test combines the measurement of Placental Growth Factor (PlGF) levels with other markers such as PAPP-A and nuchal translucency to provide a comprehensive evaluation of the pregnancy.

  • Detection of Preeclampsia: Preeclampsia is a serious condition characterized by high blood pressure and protein in the urine. The Combined Screening test can help identify women at risk for developing preeclampsia, allowing for early intervention and monitoring.
  • Assessment of Fetal Growth: By measuring PlGF levels, the test can also provide information about the baby's growth and development. Abnormal PlGF levels may indicate a risk for intrauterine growth restriction (IUGR) or other fetal complications.
  • Risk Stratification: The Combined Screening test can help healthcare providers stratify pregnant women into low, intermediate, or high-risk categories based on their individual risk factors. This information can guide decisions regarding further testing or monitoring during the pregnancy.

Overall, the Combined Screening with PlGF- Roche (Astraia) Test is an important tool in prenatal care that can help identify and manage potential risks to both the mother and the baby, ultimately improving pregnancy outcomes.

No FAQs available.

Customer Google Rating